

1 **Effect of Prebiotic Carbohydrates on the Growth and Tolerance of**  
2 **Lactobacillus**

3  
4 O. Hernandez-Hernandez<sup>1</sup>, A. Muthaiyan<sup>2</sup>, F. J. Moreno<sup>3</sup>, A. Montilla<sup>3</sup>, M. L. Sanz<sup>1</sup>, S. C.  
5 Ricke<sup>2\*</sup>

6 <sup>1</sup>Instituto de Química Orgánica General (CSIC) C/ Juan de la Cierva 3, 28006, Madrid,  
7 Spain.

8 <sup>2</sup>Center for Food Safety and Department of Food Science, University of Arkansas,  
9 Fayetteville, AR, USA.

10 <sup>3</sup>Instituto de Investigación en Ciencias de la Alimentación, CIAL (CSIC-UAM) C/ Nicolás  
11 Cabrera, 9 Campus de Cantoblanco - Universidad Autónoma de Madrid, 28049 Madrid,  
12 Spain.

13  
14 \*Corresponding author:

15 Email: [sricke@uark.edu](mailto:sricke@uark.edu)

16 Tel: +1 479 5754688

17 Fax: +1 479 575 6930

24 **ABSTRACT**

25 Resistance to gastrointestinal conditions is a requirement for bacteria to be  
26 considered probiotics. In this work, we tested the resistance of six different *Lactobacillus*  
27 strains and the effect of carbon source to four different gastrointestinal conditions: presence  
28 of  $\alpha$ -amylase, pancreatin, bile extract and low pH. Novel galactooligosaccharides  
29 synthesized from lactulose (GOS-Lu) as well as commercial galactooligosaccharides  
30 synthesized from lactose (GOS-La) and lactulose were used as carbon sources and  
31 compared with glucose. In general, all strains grew in all carbon sources, although after 24  
32 h of fermentation the population of all *Lactobacillus* strains was higher for both types of  
33 GOS than for glucose and lactulose. No differences were found among GOS-Lu and GOS-  
34 La.  $\alpha$ -amylase and pancreatin resistance was retained at all times for all strains. However, a  
35 dependence on carbon source and *Lactobacillus* strain was observed for bile extract and  
36 low pH resistance. High hydrophobicity was found for all strains with GOS-Lu when  
37 compared with other carbon sources. However, concentrations of lactic and acetic acid  
38 were higher in glucose and lactulose than GOS-Lu and GOS-La. These results show that  
39 the resistance to gastrointestinal conditions and hydrophobicity is directly related with the  
40 carbon source and *Lactobacillus* strains. In this sense, the use of prebiotics as GOS and  
41 lactulose could be an excellent alternative to monosaccharides to support growth of  
42 probiotic *Lactobacillus* strains and improve their survival through the gastrointestinal tract.

43

44 **Keywords:** probiotic, prebiotic, lactobacillus, lactulose, galactooligosaccharides, tolerance

45

46       **1. INTRODUCTION**

47           Probiotics are live microorganisms (mainly lactobacillus and bifidobacteria) which  
48 administered in adequate amounts confer a health benefit to the host (FAO/WHO, 2003).  
49 The *Lactobacillus* genus is distributed in various ecological niches and is an important  
50 constituent of the human and animal gut microbiota (Charteris et al., 1997).

51           Lactobacilli are currently added to a variety of functional foods and several studies  
52 have demonstrated their beneficial properties in human health (Reid et al., 2011). However,  
53 an important requirement is that these bacteria should be able to survive gastrointestinal  
54 conditions (amylases in the oral cavity, low pH in the stomach, bile secretions and  
55 pancreatic juice in the duodenal section of the small intestine). Several *in vivo* (Jain et al.,  
56 2004; Reid, 2008; Park et al., 2008) and *in vitro* (Charteris et al., 1998; Fernandez et al.,  
57 2003; Pitino et al., 2010) studies have indicated that some *Lactobacillus* strains only  
58 partially survive the passage through gastrointestinal tract and it is said that generally a  
59 population of  $10^7 - 10^9$  CFU per mL of bacterial cells should be present in foods in order to  
60 colonize, at least temporally, the intestine (Lee & Salminen, 1995). Nevertheless, it has  
61 been observed that only specific strains can survive these conditions. In this sense,  
62 Fernández et al. (2003) reported that *L. acidophilus* and *L. gasseri* strains were resistant to  
63 low pH and to the presence of different gastrointestinal enzymes. Similarly, Pitino et al.  
64 (2010) observed that six different strains of *L. rhamnosus* were resistant to a simulated  
65 human digestion process and Charteris et al. (1998) studied the survival of seven different  
66 *Lactobacillus* species where *L. fermentum* KLD was considered intrinsically resistant;  
67 additionally, these authors found that the addition of milk protein improved the tolerance of  
68 the probiotics to gastrointestinal conditions. Similar results have been found by Chavarri et

69 al. (2010) and Madureira et al. (2010) using microencapsulation with alginate-chitosan and  
70 whey cheese matrix, respectively.

71 Kimoto-Nira et al. (2010) have recently studied the resistance of *Lactococcus lactis*  
72 G50 grown in six different non-prebiotic carbohydrates (fructose, glucose, galactose,  
73 xylose, lactose and sucrose) under simulated gastrointestinal stress. The survival behaviour  
74 of G50 strain was found to be dependent on the carbon source where they were grown.  
75 However, to the best of our knowledge the resistance to gastrointestinal conditions of  
76 *Lactobacillus* strains grown in prebiotic carbohydrates has rarely been considered. Valerio  
77 et al. (2006) reported the protective effect of artichokes on different probiotics strains in the  
78 gastrointestinal tract could be hypothetically attributed to the presence of prebiotic  
79 carbohydrates and to the physical structure of the vegetable matrix.

80 Prebiotics are defined as “nondigestible food ingredients that beneficially affects  
81 host by selectively stimulating the growth and/or activity of one or a limited number of  
82 bacteria in the colon” (Gibson et al., 2004). Some prebiotic carbohydrates are currently  
83 available in the market, such as fructooligosaccharides, lactulose, inulin and  
84 galactooligosaccharides from lactose (GOS-La) (Rastall, 2010). However, currently there is  
85 considerable interest in the discovery of new carbohydrates with potential prebiotic  
86 properties. Among them, galactooligosaccharides from lactulose (GOS-Lu) have recently  
87 been studied (Cardelle-Cobas et al., 2008; Martinez-Villaluenga et al., 2008). GOS-Lu can  
88 be obtained by transgalactosylation reaction of the lactulose by the action of  $\beta$ -  
89 galactosidases from different bacterial sources (Cardelle-Cobas et al., 2008; Martinez-  
90 Villaluenga et al., 2008). Recently, it has been reported that GOS-Lu have the ability to  
91 promote the growth of bifidobacteria using *in vitro* fermentation systems with human fecal

92 cultures in a similar manner as the more highly recognised prebiotic GOS-La (Cardelle-  
93 Cobas et al., 2009).

94 Therefore, the aim of this study was to investigate the growth of six *Lactobacillus*  
95 strains, normally used in fermented food, with different prebiotics (lactulose, GOS from  
96 lactose and GOS from lactulose) as carbon sources and to determine their resistance to  
97 different gastrointestinal conditions (amylases, low pH, bile extract and pancreatin).  
98 Hydrophobicity as a measure of potential adhesion of lactobacillus, as well as lactic and  
99 acetic acid concentrations produced during incubation were also evaluated.

100

## 101 2. MATERIALS AND METHODS

### 102 2.1. Chemicals

103 Glucose, lactulose, bile extract, pancreatin and  $\alpha$ -amylase (1440 units/mg protein)  
104 from porcine pancreas,  $\beta$ -galactosidase from *Aspargillus oryzae* (8.0 units/mg protein) and  
105 *n*-hexadecane was purchased from Sigma-Aldrich (St. Louis, USA). The bacteriological  
106 growth media supplements were obtained from EMD Chemicals, Gibbstown, NJ. The  
107 galactooligosaccharide from lactose (GOS-La) was obtained from Vivinal-GOS<sup>®</sup>, kindly  
108 provided by Friesland Foods Domo (Zwolle, The Netherlands). This product has a 73 wt%  
109 dry matter, the composition of which was 60 wt% GOS, 20 wt% lactose, 19 wt% glucose  
110 and 1 wt% galactose, as stated by the supplier. Duphalac<sup>®</sup> (Solvay Pharma, Brussels,  
111 Belgium) was used to obtain the galactooligosaccharides from lactulose (GOS-Lu).

112

### 113 2.2. Preparation of galactooligosaccharides

114 In order to purify the GOS-La, the industrial product Vivinal-GOS<sup>®</sup> was  
115 fractionated using size exclusion chromatography, following the method reported by

116 Hernandez et al. (2009) with some modifications. In brief, 80 mL of Vivinal-GOS<sup>®</sup> (25 %  
117 w/v) were injected in a Bio-Gel P2 (Bio-Rad Hercules, CA, USA) column (90 x 5 cm)  
118 using water as mobile phases, at 1.5 mL min<sup>-1</sup>. Sixty fractions of 10 mL were collected,  
119 after the elution of void volume. The fractions degree polymerization (DP) was determined  
120 by electrospray ionization mass spectrometry (ESI-MS) at positive mode, ranging from  
121 monosaccharides to octasaccharides. Fractions with DP ≥ 3 were pooled and freeze dried.

122 GOS from lactulose were obtained following the method previously described  
123 (Clemente et al., 2011). A solution (450 g L<sup>-1</sup>) of lactulose (Duphalac<sup>®</sup>) was dissolved in 50  
124 mM sodium phosphate buffer and 1 mM MgCl<sub>2</sub>, pH 6.5, after addition of 8 U mL<sup>-1</sup> of β-  
125 galactosidase from *Aspergillus oryzae* (Sigma, St. Louis, MO USA), and incubation at 50  
126 °C for 20 h under continuous agitation at 300 rpm. After incubation, the mixtures were  
127 immediately immersed in boiling water for 5 min to inactivate the enzymes. The DP of  
128 initial GOS-Lu mixture contained from monosaccharides to octasaccharides. Subsequently,  
129 the GOS-Lu mixture was fractionated using size exclusion chromatography in order to  
130 remove mono- and disaccharides, following the previous methodology applied to Vivinal-  
131 GOS<sup>®</sup>.

132

### 133 2.3. Bacterial Strains

134 *Lactobacillus bulgaricus* ATCC7517 (LB), *Lactobacillus casei* ATCC11578 (LC),  
135 *Lactobacillus delbrueckii* subsp. *lactis* ATCC4797 (LD), *Lactobacillus plantarum*  
136 ATCC8014 (LP1), *Lactobacillus plantarum* WCFS1 (LP2) and *Lactobacillus sakei* 23K  
137 (LS) were purchased in lyophilized form and maintained at -80 °C for long-term storage.  
138 All these strains are considered as probiotics as previously reported **previously** in different  
139 **studies** (Jain et al., 2004; Reid, 2008; Park et al., 2008).

140 Freeze-dried strains were grown in Lactobacilli MRS broth or in Lactobacilli MRS  
141 agar (EMD Chemicals, Gibbstown, NJ) at 37 °C in an anaerobic chamber (10% CO<sub>2</sub>: 5%  
142 H<sub>2</sub>: 85% N<sub>2</sub>) (Coy Laboratory Products, Ann Arbor, MI) after transfer through an airlock  
143 with two exchanges of N<sub>2</sub> gas followed by one exchange of the oxygen-free mixed gas of  
144 the same composition as within the chamber.

145

#### 146 *2.4.Growth conditions*

147 Bacteria were grown in MRS basal media carbohydrate free containing: 10 g L<sup>-1</sup>  
148 protease peptone, 10 g L<sup>-1</sup> beef extract, 5 g L<sup>-1</sup> yeast extract, 1 g L<sup>-1</sup> Tween 80, 2 g L<sup>-1</sup>  
149 ammonium citrate, 5 g L<sup>-1</sup> sodium acetate, 0.1 g L<sup>-1</sup> magnesium sulphate, 0.05 g L<sup>-1</sup>  
150 manganese sulphate, 2 g L<sup>-1</sup> dipotassium sulphate and 0.5 g L<sup>-1</sup> cysteine-HCl. Glucose,  
151 lactulose, GOS-La and GOS-Lu were dissolved in water (10 % w/v) and sterilized by  
152 filtration, this solution was added to MRS basal media to a final concentration of 1% w/v.  
153 The incubation was carried out under anaerobic conditions at 37 °C. Inoculum was prepared  
154 from 48 h MRS grown *Lactobacillus* cells and approximately 1 x 10<sup>7</sup> CFU per mL of each  
155 *Lactobacillus* strain (individually) was added to the MRS basal media containing 1% w/v  
156 of glucose, lactulose, GOS-La or GOS-Lu and incubated under anaerobic conditions, at  
157 37°C during 24, 48, 72 and 120 hours. Viable count was carried out by plating on MRS  
158 agar in duplicate. All experiments were carried out in triplicate.

159

#### 160 *2.5.Lactic and acetic acid analyses*

161 The incubated samples at 24, 48, and 72 h were centrifuged at 13,000 g for 10 min  
162 to remove all insoluble particles and the lactic and acetic acid fermentation products were  
163 quantified using a BioRad HPX-87H HPLC column (Watford, UK) at 50 °C, with a 0.005

164 mM H<sub>2</sub>SO<sub>4</sub> as the mobile phase, in isocratic mode, at a flow rate of 0.6 mL min<sup>-1</sup> (Sanz et  
165 al., 2005). The analyses were carried out in triplicate.

166 Since minor levels of acetic acid were initially present in the MRS broth, this value  
167 was quantified and subtracted from the amounts calculated for the samples subjected to  
168 incubation.

169

### 170 *2.6.Tolerance to different gastrointestinal conditions*

171 One mL aliquots of cultures was taken after 48 h of fermentation as outlined  
172 previously and then centrifuged for 15 min, at 4 °C and 8,000 rpm. The cells were washed  
173 twice using PBS buffer. The cell pellet was re-suspended in 1 mL of PBS pH 7.0 with: (i)  
174 bile extract (0.3 % w/v), or (ii) α-amylase (100 U mL<sup>-1</sup>) or (iii) pancreatin (0.2 % w/v; a  
175 mixture of digestive enzyme secreted by the pancreas and commonly used to simulate the  
176 pancreatic juice present in the intestinal digestion), or (iv) 1 mL of saline solution adjusting  
177 the pH with HCl 0.1 M (0.85 % w/v; pH 2.5) for low pH studies. The percentage of  
178 survival was calculated from triplicate experiments using the following formula:

$$179 \quad \% \text{ survival} = (\beta / \alpha) * 100$$

180 Where α is the CFU per mL of the assayed strain at 48 h and β the CFU per mL of  
181 the same strain after incubation with the different gastrointestinal conditions.

182

### 183 *2.7.Hydrophobicity of bacteria*

184 Hydrophobicity was determined following the method proposed by Kimoto-Nira et  
185 al. (2010) with some modifications. After 48 h of incubation the bacteria grown on the  
186 different substrates (glucose, lactulose, GOS-La and GOS-Lu) were washed and suspended  
187 in PBS in order to obtain an OD<sub>620</sub> of 1.0. One millilitre of *n*-hexadecane was added to 1.0



188 mL of cell suspensions. The solution was incubated during 10 min at 30°C, mixed during  
189 60 s and then left to stand for 15 min. The aqueous phase was removed and the OD<sub>620</sub>  
190 determined. The percentage of hydrophobicity was calculated using the following equation:  
191  $100 \times [1 - (\text{Initial OD}_{620} / \text{OD}_{620} \text{ after incubation with } n\text{-hexadecane})]$ . The analyses were  
192 carried out by triplicate.

193

#### 194 *2.8. Statistical analyses*

195 Statistical analyses were performed using Statistica for Windows version 6 (2002)  
196 by Statsoft Inc. (Tulsa, **OK**, USA). Differences between bacterial survival, % of  
197 hydrophobicity and lactic and acetic acid concentrations were tested using one-way  
198 ANOVA test, followed by a least significant difference (LSD) test as a post hoc  
199 comparison of means (P<0.05).

200

### 201 3. RESULTS AND DISCUSSION

202

#### 203 3.1. Growth of *Lactobacillus* strains with prebiotic sources

204 The growth profiles of six different *Lactobacillus* strains in the presence of  
205 lactulose, GOS-La, GOS-Lu are shown in Figure 1. Glucose was also included in this study  
206 for comparative purposes. All *Lactobacillus* strains grew during the first 24 h for all the  
207 substrates. Higher growth rates were observed for LC and LD with glucose and lactulose  
208 than with GOS-La and GOS-Lu substrates, whereas for LP1, LP2 and LS the initial growth  
209 rates were similar for all carbohydrates tested, and for LB the lowest initial growth was  
210 obtained with glucose. However, after this time, growth rates of all *Lactobacillus* strains  
211 decreased quickly when they were grown with glucose and lactulose, whilst all strains kept  
212 constant or were slightly modified with GOS-Lu and GOS-La. This response could be  
213 attributed to different reasons. It is known that carbohydrates with longer chain lengths are  
214 fermented more slowly (Cummings et al., 2001) which is in agreement with the  
215 fermentation kinetics of lactobacillus strains exhibited in presence of GOS-La and GOS-Lu  
216 (Figure 1). Likewise, this could also explain the initial higher growth observed for LC and  
217 LD with glucose and lactulose at 24 hours of incubation. However, no notable differences  
218 were detected between GOS-La and GOS-Lu for all fermentation times and strains. Similar  
219 behaviour has previously been reported in some bifidobacteria species, using  
220 fructooligosaccharides and inulin as the carbon sources, where the oligomers with high  
221 molecular weight promoted a higher bacterial growth than other substrates with lower  
222 molecular weight (Vernazza et al., 2006).

223 Conversely the metabolism of large carbohydrate molecules requires the use of  
224 glycosidases and specific transport mechanisms for the hydrolysis products (Vernazza et

225 al., 2006). In *Lactobacillus* genus, the  $\beta$ -galactosidases are specifically located in the  
226 cytoplasm (Fortina et al., 2003) which implies that for the metabolization of GOS,  
227 *Lactobacillus* strains need a transport system in order to hydrolyze these oligosaccharides  
228 into the cell by  $\beta$ -galactosidases. This could explain the slower growth of LC and LD  
229 strains at 24 h with GOS-Lu and GOS-La compared with glucose and lactulose; however,  
230 for LP1, LP2 and LS, the similar values for initial growth provide evidence for a strain-  
231 dependence on the assimilation of carbon source.

232 Furthermore, it has been previously observed that the monomeric composition,  
233 polymerization degree and type of glycosidic linkages can affect the growth of probiotic  
234 strains (Rastall et al., 2005). GOS-La obtained from Vivinal-GOS<sup>®</sup> primarily consist of  $\beta$ -  
235 (1-4) linkages (Coulier et al. 2009; Rastall, 2010) and GOS-Lu consist of  $\beta$ -(1-6), being the  
236 most abundant trisaccharide 6'-galactosyl-lactulose (Hernandez-Hernandez et al., 2011).  
237 Cardelle-Cobas et al. (2011) when studying the effect of different trisaccharides isolated  
238 from GOS-Lu and GOS-La mixtures on different bacteria strains, including *Lactobacillus*,  
239 reported a preference for linkages  $\beta$ -(1-6) instead of  $\beta$ -(1-4); however, the results obtained  
240 in our work showed no differences in growth responses of *Lactobacillus* strains using GOS-  
241 Lu or GOS-La.

242

### 243 *3.2.Lactic and acetic acid production*

244 In general, for all strains and carbon sources tested, concentrations of lactic acid  
245 were higher than that of acetic acid (**Table 1**). *Lactobacillus* strains grown in glucose and  
246 lactulose generated higher concentrations of lactic acid than GOS-La and GOS-Lu, whilst  
247 similar levels of acetic acid were found for all assayed carbohydrates. The low amount of  
248 lactic acid produced in GOS grown culture could be due to the slower and prolonged

249 fermentation by the bacterial strains. This could also have an influence on the higher  
250 survival rate of *Lactobacillus* strains grown in GOS substrates (Figure 1), as a lower acid  
251 production leads to less acidic pH values. No significant differences were, in general,  
252 detected among the different incubation times either for each carbohydrate or between  
253 GOS-La and GOS-Lu. Lactic and acetic acids are fermentation products of lactic acid  
254 bacteria (Lindgren and Dobrogosz, 1990). These acids decrease the pH and consequently  
255 can prevent the over growth of pathogenic bacteria in the intestine (Roy et al., 2006). Short  
256 chain fatty acids (SCFA) such as acetic and lactic acids are involved in multiple beneficial  
257 effects on the host. Acetic acid is metabolised by different human tissues representing a  
258 route to obtain energy from non-digestible carbohydrates (Roy et al., 2006; Roberfroid et  
259 al., 2010); however, lactic and acetic acids are assimilated by different species present in  
260 the gut microbiota, producing butyric acid which can be involved in multiple positive  
261 effects such as the reduction of colon cancer risk (Roy et al., 2006; Falony et al. 2009;  
262 Roberfroid et al., 2010).

263         These results support that *Lactobacillus* strains are able to hydrolyze GOS  
264 synthesized from lactose and lactulose, as well as lactulose to produce beneficial  
265 metabolites as final products.

266

### 267         3.3. Tolerance to different gastrointestinal conditions

268         The survival responses of the *Lactobacillus* strains, previously grown in the  
269 different carbohydrates tested, after 1 and 3 hours of being exposed to different  
270 gastrointestinal conditions are shown in **Tables 2** and **3**.

271         All the strains survived after 1 and 3 h of exposure to  $\alpha$ -amylase and pancreatin  
272 treatments (**Table 2**), although a significant decrease in survival of LS incubated with

273 lactulose in the presence of amylase was observed. Survival rate values were greater than  
274 100 % in some cases which could be due to the presence of low molecular weight  
275 carbohydrates in the commercial enzymatic preparations. Pitino et al. (2010) reported an  
276 increase on the survival of some strains of *L. rhamnosus* during simulation of duodenal  
277 digestion, due to the presence of a carbon source in the MRS broth used as the vehicle for  
278 digestion of the cells. Similar data were found by Kimoto-Nira et al. (2009) for  
279 *Lactococcus lactis* in media containing bile salts and lactose as carbon source.

280 Survival to bile extract appeared to be dependent on the carbon source and the  
281 *Lactobacillus* strain at both tested times (**Table 3**). After 1 hour a general decline in  
282 bacteria numbers was detected for all strains and carbon sources, with the exception of LB  
283 grown on glucose and lactulose and LP1 on lactulose. This decrease was greater at 3 hours  
284 of treatment. LC and LD exhibited the lowest survival rates for all carbohydrate sources,  
285 whereas LP1 was the most resistant strain.

286 Regarding LB, its survival after bile treatment was higher when it was incubated  
287 with glucose and lactulose, whereas LC survived better when it was incubated with GOS-  
288 Lu and GOS-La as compared to non-survival in the presence of glucose and lactulose after  
289 3 hours of fermentation. LD grown on lactulose exhibited its highest survival rate in the  
290 presence of the bile extract. Lower significant differences in bile tolerance were detected  
291 for LP1, LP2 and LS grown on the different carbohydrate sources.

292 Charteris et al. (1998) reported that a level of survival higher than 30% would be  
293 considered intrinsically tolerant to gastric transit when using simulated gastric and  
294 pancreatic juices. Although the results presented here are based on resistance to bile  
295 extracts, this value could be considered to classify the *Lactobacillus* strains, tested for the  
296 different gastrointestinal conditions, as being as tolerant or not tolerant. Following this

297 premise, most of the strains grown in the different carbohydrates used could be considered  
298 as bile tolerant, with the exception of LC using glucose and lactulose. Similarly, Fernandez  
299 et al. (2003) and Koll et al. (2010) reported tolerance to bile salts at 0.15 and 2% w/v,  
300 respectively, of different *Lactobacillus* strains grown in MRS agar.

301 Tolerance to gastric pH (2.5) expressed as % survival is shown in **Table 3**. In  
302 general, after 1 h of exposition, significant survival decreases were observed for all assayed  
303 strains. LB and LS grown on prebiotic carbohydrates exhibited a higher resistance to pH  
304 conditions than the strains grown on glucose, whereas LC and LD grown on glucose were  
305 more tolerant. LP1 and LP2 grown on lactulose or glucose exhibited higher resistance to  
306 low pH values. Although gastric emptying is strongly influenced by volume and  
307 composition of gastric contents, type of meal and/or gastrointestinal disorders (Bolondi et  
308 al., 1985), the average time for 50% of gastric emptying has been estimated to be  
309 approximately 1.2 hours (Read et al., 1986). This means that physiologically relevant levels  
310 of most of the studied *Lactobacillus* strains could be able to reach further down the  
311 gastrointestinal tract. Finally, at extreme exposure times to treatment (3 h), only LP2 grown  
312 on lactulose, GOS-La or GOS-Lu, LD grown on glucose and LS grown on GOS-Lu could  
313 be detected.

314

#### 315 *3.4. Hydrophobicity of bacteria*

316 The percentage of hydrophobicity of all strains after 48h of fermentation is shown  
317 in Table 4. It is worth noting that LB, LC and LD grown with GOS-Lu exhibited the  
318 highest values of hydrophobicity, whereas hydrophobicity of LP1 and LS was higher when  
319 they were grown on GOS-La. Both prebiotic carbohydrates also contributed to the higher  
320 hydrophobicity values of LP2. Hydrophobic index of bacteria is related to their adhesion

321 capacity to intestinal cells (Wadstrom et al., 1987). This capacity is necessary for the  
322 bacteria to colonize, at least temporally, the intestine and consequently, they may be  
323 considered as probiotics. Therefore, LB, LC and LD strains grown on GOS-Lu and LC,  
324 LP1 and LS strains grown on GOS-La could exhibit the higher adhesion capacity. It has  
325 also been reported that hydrophobicity index varies depending on the strain and the carbon  
326 source used (Kimoto-Nira et al., 2010) which is in good agreement with our results.

327

328         In conclusion, resistance to gastrointestinal conditions (mainly to bile extracts and  
329 gastric pH values) and bacterial hydrophobicity depend highly on carbohydrates used as  
330 carbon source and the *Lactobacillus* strain. Growth of some *Lactobacillus* strains on  
331 different prebiotics could help to increase their resistance to gastrointestinal conditions,  
332 thus, enhancing their survival through the gastrointestinal tract, as well as to promote their  
333 adhesion capacity. Additionally, food matrix effects may also contribute to the ability of a  
334 probiotic to survive through the gastrointestinal tract (Sanders and Marco, 2010). Thus,  
335 several studies have previously shown that the inclusion of milk-based products improved  
336 the resistance to gastrointestinal conditions of different probiotics including some  
337 *Lactobacillus* strains (Charteris et al, 1998; Fernández et al, 2003; Madureira et al, 2010;  
338 Martinez et al, 2011). A possible explanation for this response is that milk proteins could  
339 act as buffering agents and/or inhibitors of digestive proteases (Charteris et al., 1998). On  
340 the basis of these studies, it could be expected that the combined use of milk-based  
341 products and GOS-La or GOS-Lu might increase the survival of the assayed *Lactobacillus*  
342 strains. These findings may help to expand the applications of lactulose, and  
343 galactooligosaccharides derived from lactulose and lactose in synbiotic products with  
344 important applications in the design of new functional food ingredients.

345

346 **ACKNOWLEDGEMENTS**

347           The authors gratefully acknowledge financial support from Junta de Castilla-La  
348 Mancha and European regional development fund (ERDF) (POII10-0178-4685) and by  
349 Ministerio de Educación y Ciencia (Consolider Ingenio 2010 Programme FUN-C-FOOD  
350 CSD2007-00063). SCR thanks the support from USDA Food Safety Consortium and  
351 USDA **National Integrated Food Safety Initiative** IFSI grant # **2008-51110-04339**. Oswaldo  
352 Hernández-Hernández thanks the CSIC for a JAE-PreDoc PhD-grant. We thank Dr. G.  
353 Klarenbeek and Dr. J. de Slegte from Friesland Foods Domo for providing us with Vivinal-  
354 GOS<sup>®</sup>.

355

356

357

358

359

360

361

362

363

364

365 **4. REFERENCES**

366 Bolondi, L., Bortolotti, M., Santi, V., Calletti, T., Gaiani, S., & Labo, G. (1985).  
367           Measurement of gastric-emptying time by real-time ultrasonography.  
368           *Gastroenterology*, 89, 752-759.



369 Cardelle-Cobas, A., Martínez-Villaluenga, C., Villamiel, M., Olano, A., & Corzo, N.  
370 (2008). Synthesis of Oligosaccharides Derived from Lactulose and Pectinex Ultra  
371 SP-L. *Journal of Agricultural and Food Chemistry*, 56, 3328-3333.

372 Cardelle-Cobas, A., Fernández, M., Salazar, N., Martínez-Villaluenga, C., Villamiel, M.,  
373 Ruas-Madiedo, P., & de los Reyes-Gavilán, C. G. (2009). Bifidogenic effect and  
374 stimulation of short chain fatty acid production in human faecal slurry cultures by  
375 oligosaccharides derived from lactose and lactulose. *Journal of Dairy Research*, 76,  
376 317-325.

377 Cardelle-Cobas, A., Corzo, N., Olano, A., Peláez, C., Requena, T., & Ávila, M., (2011).  
378 Galactooligosaccharides derived from lactose and lactulose: Influence of structure  
379 on *Lactobacillus*, *Streptococcus* and *Bifidobacterium* growth. *International Journal*  
380 *of Food Microbiology*, 149, 81-87.

381 Charteris, W. P., Kelly, P. M., Morelli, L., & Collins, J. K. (1997). Selective detection,  
382 enumeration and identification of potentially probiotic *Lactobacillus* and  
383 *Bifidobacterium* species in mixed bacterial populations. *International Journal of*  
384 *Food Microbiology*, 35, 1-27.

385 Charteris, W. P., Kelly, P. M., Morelli, L., & Collins, J. K. (1998). Development and  
386 application of an in vitro methodology to determine the transit tolerance of  
387 potentially probiotic *Lactobacillus* and *Bifidobacterium* species in the upper human  
388 gastrointestinal tract. *Journal of Applied Microbiology*, 84, 759-768.

389 Chávarri, M., Marañón, I., Ares, R., Ibáñez, F.C., Marzo, F., and Villarán, M.d.C., 2010.  
390 Microencapsulation of a probiotic and prebiotic in alginate-chitosan capsules  
391 improves survival in simulated gastro-intestinal conditions. *International Journal of*  
392 *Food Microbiology*, 142, 185-189.

393 Clemente, A., Hernández-Hernández, O., Laparra, M., Montilla, A., Moreno, F.J., Olano,  
394 A., Ruiz, L., Sanz M.L., & Sanz, Y. Multi-functional galacto-oligosaccharides  
395 derived from lactulose with immunomodulatory and prebiotic activities. Spanish  
396 patent P201130784, 2011.

397 Coulier, L., Timmermans, J., Bas, R., Van Den Dool, R., Haaksman, I., Klarenbeek, B.,  
398 Slaghek, T., & Van Dongen, W. (2009). In-depth characterization of prebiotic  
399 galacto-oligosaccharides by a combination of analytical techniques. *Journal of*  
400 *Agricultural and Food Chemistry*, 57, 8488-8495.

401 Cummings, J. H., Macfarlane, G. T., & Englyst, H. N. (2001). Prebiotic digestion and  
402 fermentation. *American Journal of Clinical Nutrition*, 73, 415S-420S.

403 Falony, G. & De Vuyst, L. (2009). Ecological interections of bacteria in the human gut, p.  
404 641-682. In: Charalampopoulos, D. and Rastall, R. (Eds.), *Prebiotics and Probiotics*  
405 *Science and Technology* (641-682). Springer, New York.

406 FAO/WHO. (2003). *Probiotics in Food. Health and nutritional properties and guidelines*  
407 *for evaluation*. Rome-Italy: FAO/WHO, (Volume 85).

408 Fernandez, M. F., Boris, S., & Barbes, C. (2003). Probiotic properties of human lactobacilli  
409 strains to be used in the gastrointestinal tract. *Journal of Applied Microbiology*, 94,  
410 449-455.

411 Fortina, M. G., Ricci, G., Mora, D., Guglielmetti, S., & Manachini, P. L. (2003). Unusual  
412 organization for lactose and galactose gene clusters in *Lactobacillus helveticus*.  
413 *Applied and Environmental Microbiology*, 69, 3238-3243.

414 Gibson, G. R., Probert, H. M., Loo, J. V., Rastall, R. A., & Roberfroid, M. B. (2004).  
415 Dietary modulation of the human colonic microbiota: updating the concept of  
416 prebiotics. *Nutrition Research Reviews*, 17, 259.

417 Hernández, O., Ruiz-Matute, A.I., Olano, A., Moreno, F.J., and Sanz, M.L., 2009.  
418 Comparison of fractionation techniques to obtain prebiotic galactooligosaccharides.  
419 *International Dairy Journal*, 19, 531-536.

420 Hernández-Hernández, O., Montañés, F., Clemente, A., Moreno, F. J., & Sanz, M. L.,  
421 2011. Characterization of galactooligosaccharides derived from lactulose. *Journal*  
422 *of Chromatography A*, 1218, 7691-7696.

423 Jain, P. K., McNaught, C. E., Anderson, A. D. G., MacFie, J., & Mitchell, C. J., (2004).  
424 Influence of synbiotic containing *Lactobacillus acidophilus* La5, *Bifidobacterium*  
425 *lactis* Bb 12, *Streptococcus thermophilus*, *Lactobacillus bulgaricus* and  
426 oligofructose on gut barrier function and sepsis in critically ill patients: A  
427 randomised controlled trial. *Clinical Nutrition*, 23, 467-475.

428 Kimoto-Nira, H., Kobayashi, M., Nomura, M., Sasaki, K., & Suzuki, C. (2009). Bile  
429 resistance in *Lactococcus lactis* strains varies with cellular fatty acid composition:  
430 Analysis by using different growth media. *International Journal of Food*  
431 *Microbiology*, 131, 183-188.

432 Kimoto-Nira, H., Suzuki, C., Sasaki, K., Kobayashi, M., & Mizumachi, K. (2010). Survival  
433 of a *Lactococcus lactis* strain varies with its carbohydrate preference under in vitro  
434 conditions simulated gastrointestinal tract. *International Journal of Food*  
435 *Microbiology*, 143, 226-229.

436 Koll, P., Mandar, R., Smidt, I., Hutt, P., Truusalu, K., Mikelsaar, R.H., Shchepetova, J.,  
437 Krogh-Andersen, K., Marcotte, H., Hammarstrom, L., & Mikelsaar, M., 2010.

438 Screening and evaluation of human intestinal lactobacilli for the development of  
439 novel gastrointestinal probiotics. *Current Microbiology*, 61, 560-566.

440 Lee, Y. K., & Salminen, S. (1995). The coming of age of probiotics. *Trends in Food*  
441 *Science & Technology*, 6, 241-245.

442 Lindgren, S. E., & Dobrogosz, W. J. (1990). Antagonistic activities of lactic acid bacteria in  
443 food and feed fermentations. *FEMS Microbiology Letters*, 87, 149-163.

444 Madureira, A.R., Amorim, M., Gomes, A.M., Pintado, M.E., and Malcata, F.X., 2011.  
445 Protective effect of whey cheese matrix on probiotic strains exposed to simulated  
446 gastrointestinal conditions. *Food Research International*, 44, 465-470.

447 Martinez, R.C.R., Aynaou, A.-E., Albrecht, S., Schols, H.A., De Martinis, E.C.P.,  
448 Zoetendal, E.G., Venema, K., Saad, S.M.I., and Smidt, H., 2011. In vitro evaluation  
449 of gastrointestinal survival of *Lactobacillus amylovorus* DSM 16698 alone and  
450 combined with galactooligosaccharides, milk and/or *Bifidobacterium animalis*  
451 subsp. lactis Bb-12. *International Journal of Food Microbiology*, 149, 152-158.

452 Martinez-Villaluenga, C., Cardelle-Cobas, A., Olano, A., Corzo, N., Villamiel, M., &  
453 Jimeno, M. L. (2008). Enzymatic synthesis and identification of two trisaccharides  
454 produced from lactulose by transgalactosylation. *Journal of Agricultural and Food*  
455 *Chemistry*, 56, 557-563.

456 Park, C. W., Youn, M., Jung, Y. M., Kim, H., Jeong, Y., Lee, H.- K., Kim, H. O., Lee, I.,  
457 Lee, S. W., Kang, K. H., & Park, Y. -H. (2008). New functional probiotic  
458 *Lactobacillus sakei* probio 65 alleviates atopic symptoms in the mouse. *Journal of*  
459 *Medicinal Food*, 11, 405-412.

460 Pitino, I., Randazzo, C. L., Mandalari, G., Lo Curto, A., Faulks, R. M., Le Marc, Y.,  
461 Bisignano, C., Caggia, C., & Wickham, M. S. J. (2010). Survival of *Lactobacillus*

462 *rhamnosus* strains in the upper gastrointestinal tract. *Food Microbiology*, 27, 1121-  
463 1127.

464 Rastall, R.A., Gibson, G.R., Gill, H.S., Guarner, F., Klaenhammer, T.R., Pot, B., Reid, G.,  
465 Rowland, I.R., & Sanders, M.E., 2005. Modulation of the microbial ecology of the  
466 human colon by probiotics, prebiotics and synbiotics to enhance human health: An  
467 overview of enabling science and potential applications. *FEMS Microbiology*  
468 *Ecology*, 52, 145-152.

469 Rastall, R. A. (2010). Functional Oligosaccharides: Application and Manufacture. *Annual*  
470 *Review of Food Science and Technology*, 1, 305-339.

471 Read, N.W., Aljanabi, M.N., Holgate, A.M., Barber, D.C., and Edwards, C.A., 1986.  
472 Simultaneous measurement of gastric-emptying, small-bowel residence and colonic  
473 filling of a solid meal by the use of the gamma-camera. *Gut*, 27, 300-308.

474 Reid, G., 2008. Probiotics and prebiotics – Progress and challenges. *International Dairy*  
475 *Journal*, 18, 969-975.

476 Reid, G., Younes, J. A., Van der Mei, H. C., Gloor, G. B., Knight, R., & Busscher, H. J.  
477 (2011). Microbiota restoration: natural and supplemented recovery of human  
478 microbial communities. *Nature Reviews Microbiology*, 9, 27-38.

479 Roberfroid, M., Gibson, G.R., Hoyles, L., McCartney, A.L., Rastall, R., Rowland, I.,  
480 Wolvers, D., Watzl, B., Szajewska, H., Stahl, B., Guarner, F., Respondek, F.,  
481 Whelan, K., Coxam, V., Davicco, M.J., Leotoing, L., Wittrant, Y., Delzenne, N.M.,  
482 Cani, P.D., Neyrinck, A.M., & Meheust, A. (2010). Prebiotic effects: metabolic and  
483 health benefits. *British Journal of Nutrition*, 104, S1-S63.

484 Roy, C. C., Kien, C. L., Bouthillier, L., & Levy, E. (2006). Short-Chain Fatty Acids: Ready  
485 for prime time? *Nutrition in Clinical Practice*, 21, 351-366.

486 Sanders, M.E. and Marco, M.L. (2010). Food formats for effective delivery of probiotics.  
487 *Annual Review of Food Science and Technology, 1*, 65-85

488 Sanz, M., Gibson, G.R., and Rastall, R.A., 2005. Influence of disaccharide structure on  
489 prebiotic selectivity in vitro. *Journal of Agricultural and Food Chemistry, 53*, 5192-  
490 5199.

491 Valerio, F., De Bellis, P., Lonigro, S.L., Morelli, L., Visconti, A., and Lavermicocca, P.,  
492 2006. In vitro and in vivo survival and transit tolerance of potentially probiotic  
493 strains carried by artichokes in the gastrointestinal tract. *Applied and Environmental*  
494 *Microbiology, 72*, 3042-3045.

495 Vernazza, C. L., Gibson, G. R., & Rastall, R. A. (2006). Carbohydrate preference, acid  
496 tolerance and bile tolerance in five strains of Bifidobacterium. *Journal of Applied*  
497 *Microbiology, 100*, 846-853.

498 Wadstrom, T., Andersson, K., Sydow, M., Axelsson, L., Lindgren, S., & Gullmar, B.  
499 (1987). Surface-properties of lactobacilli isolated from the small-intestine of pigs.  
500 *Journal of Applied Bacteriology, 62*, 513-520.



1 **Table 1.** Lactic acid and acetic acid concentrations (mM) after 24, 48 and 72 h of fermentation using glucose, lactulose, GOS from  
 2 lactulose (GOS-Lu) and from lactose (GOS-La). LB (*L. bulgaricus* ATCC7517), LC (*L. casei* ATCC11578), LD (*L. delbrueckii* subsp.  
 3 *Lactis* ATCC4797), LP1 (*L. plantarum* ATCC8014), LP2 (*L. plantarum* WCFS1), LS (*L. sakei* 23K).  
 4

| Carbon Source | Acid   | Time (h) | LB                             | LC                             | LD                             | LP1                            | LP2                            | LS                            |
|---------------|--------|----------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|-------------------------------|
| Glucose       | Lactic | 24       | 209.70 (0.20) <sup>*efg</sup>  | 178.54 (14.71) <sup>efg</sup>  | 203.52 (1.92) <sup>efg</sup>   | 184.33 (23.85) <sup>efg</sup>  | 203.18 (5.57) <sup>efg</sup>   | 189.12 (6.32) <sup>efg</sup>  |
|               |        | 48       | 228.67 (27.53) <sup>g</sup>    | 197.93 (29.10) <sup>efg</sup>  | 203.09 (0.44) <sup>efg</sup>   | 184.55 (29.74) <sup>efg</sup>  | 208.12 (0.40) <sup>efg</sup>   | 192.89 (16.52) <sup>efg</sup> |
|               |        | 72       | 214.89 (5.69) <sup>fg</sup>    | 189.86 (23.11) <sup>efg</sup>  | 199.74 (0.40) <sup>efg</sup>   | 230.39 (41.87) <sup>g</sup>    | 199.79 (3.62) <sup>efg</sup>   | 198.20 (9.37) <sup>efg</sup>  |
|               | Acetic | 24       | 36.76 (2.89) <sup>abcde</sup>  | 34.34 (2.17) <sup>abc</sup>    | 33.61 (1.15) <sup>abc</sup>    | 32.68 (4.37) <sup>ab</sup>     | 32.82 (0.49) <sup>ab</sup>     | 37.37 (4.84) <sup>abcde</sup> |
|               |        | 48       | 42.65 (0.91) <sup>abcde</sup>  | 31.71 (1.34) <sup>a</sup>      | 31.97 (1.13) <sup>a</sup>      | 33.67 (3.10) <sup>abc</sup>    | 34.87 (0.22) <sup>abc</sup>    | 35.42 (0.44) <sup>abcd</sup>  |
|               |        | 72       | 38.52 (3.94) <sup>abcde</sup>  | 31.04 (0.14) <sup>a</sup>      | 39.16 (14.93) <sup>abcde</sup> | 40.65 (8.53) <sup>abcde</sup>  | 31.35 (0.89) <sup>a</sup>      | 37.11 (2.68) <sup>abcde</sup> |
| Lactulose     | Lactic | 24       | 180.67 (25.27) <sup>efg</sup>  | 154.68 (3.47) <sup>de</sup>    | 165.38 (3.50) <sup>efg</sup>   | 199.46 (1.36) <sup>efg</sup>   | 201.05 (6.86) <sup>efg</sup>   | 158.91 (1.39) <sup>def</sup>  |
|               |        | 48       | 215.54 (26.31) <sup>fg</sup>   | 208.51 (13.35) <sup>efg</sup>  | 203.18 (7.44) <sup>efg</sup>   | 204.92 (3.37) <sup>efg</sup>   | 206.51 (1.45) <sup>efg</sup>   | 195.12 (7.39) <sup>efg</sup>  |
|               |        | 72       | 202.73 (10.70) <sup>efg</sup>  | 200.28 (3.02) <sup>efg</sup>   | 204.26 (0.51) <sup>efg</sup>   | 227.11 (36.28) <sup>g</sup>    | 203.36 (6.14) <sup>efg</sup>   | 202.85 (2.10) <sup>efg</sup>  |
|               | Acetic | 24       | 42.38 (0.90) <sup>abcde</sup>  | 38.39 (1.57) <sup>abcde</sup>  | 37.95 (1.93) <sup>abcde</sup>  | 49.11 (16.90) <sup>abcde</sup> | 46.66 (1.25) <sup>abcde</sup>  | 48.70 (5.52) <sup>abcde</sup> |
|               |        | 48       | 49.46 (3.45) <sup>abcde</sup>  | 37.95 (4.93) <sup>abcde</sup>  | 32.41 (5.85) <sup>ab</sup>     | 42.19 (1.08) <sup>abcde</sup>  | 37.99 (6.26) <sup>abcde</sup>  | 45.07 (3.18) <sup>abcde</sup> |
|               |        | 72       | 42.96 (6.43) <sup>abcde</sup>  | 35.03 (2.19) <sup>abc</sup>    | 31.84 (0.56) <sup>a</sup>      | 48.42 (6.61) <sup>abcde</sup>  | 35.33 (3.20) <sup>abcd</sup>   | 44.12 (7.82) <sup>abcde</sup> |
| GOS-Lu        | Lactic | 24       | 69.20 (1.52) <sup>abc</sup>    | 183.87 (29.23) <sup>efg</sup>  | 42.90 (6.90) <sup>ab</sup>     | 63.61 (0.94) <sup>abc</sup>    | 66.72 (6.73) <sup>abc</sup>    | 67.42 (4.53) <sup>abc</sup>   |
|               |        | 48       | 80.73 (4.40) <sup>abc</sup>    | 40.42 (2.05) <sup>ab</sup>     | 35.56 (9.37) <sup>ab</sup>     | 75.06 (5.23) <sup>abc</sup>    | 66.87 (6.21) <sup>abc</sup>    | 65.58 (6.10) <sup>abc</sup>   |
|               |        | 72       | 77.09 (2.50) <sup>abc</sup>    | 43.80 (0.77) <sup>ab</sup>     | 44.51 (0.99) <sup>ab</sup>     | 87.71 (12.00) <sup>abc</sup>   | 67.30 (6.55) <sup>abc</sup>    | 71.26 (8.22) <sup>abc</sup>   |
|               | Acetic | 24       | 43.02 (5.75) <sup>abcde</sup>  | 42.49 (6.04) <sup>abcde</sup>  | 42.04 (0.94) <sup>abcde</sup>  | 63.07 (2.84) <sup>e</sup>      | 31.61 (2.12) <sup>a</sup>      | 58.52 (2.72) <sup>bcde</sup>  |
|               |        | 48       | 54.13 (2.07) <sup>abcde</sup>  | 44.37 (2.05) <sup>abcde</sup>  | 43.64 (3.40) <sup>abcde</sup>  | 51.95 (0.09) <sup>abcde</sup>  | 44.42 (13.69) <sup>abcde</sup> | 53.11 (0.12) <sup>abcde</sup> |
|               |        | 72       | 48.56 (10.26) <sup>abcde</sup> | 42.32 (5.80) <sup>abcde</sup>  | 52.51 (13.54) <sup>abcde</sup> | 59.21 (11.69) <sup>cde</sup>   | 42.42 (14.22) <sup>abcde</sup> | 54.94 (2.83) <sup>abcde</sup> |
| GOS-La        | Lactic | 24       | 65.66 (2.90) <sup>abc</sup>    | 33.06 (11.05) <sup>a</sup>     | 54.12 (1.89) <sup>abc</sup>    | 46.91 (1.55) <sup>abc</sup>    | 76.81 (2.04) <sup>abc</sup>    | 77.96 (3.09) <sup>abc</sup>   |
|               |        | 48       | 83.71 (9.03) <sup>abc</sup>    | 33.20 (10.09) <sup>a</sup>     | 36.14 (12.14) <sup>ab</sup>    | 102.97 (22.16) <sup>cd</sup>   | 82.53 (0.36) <sup>abc</sup>    | 80.25 (0.28) <sup>abc</sup>   |
|               |        | 72       | 76.73 (7.55) <sup>abc</sup>    | 32.87 (9.92) <sup>a</sup>      | 33.52 (10.84) <sup>a</sup>     | 91.42 (16.87) <sup>bc</sup>    | 85.21 (2.95) <sup>abc</sup>    | 84.91 (1.25) <sup>abc</sup>   |
|               | Acetic | 24       | 45.22 (0.25) <sup>abcde</sup>  | 40.21 (12.37) <sup>abcde</sup> | 46.47 (2.11) <sup>abcde</sup>  | 57.36 (1.97) <sup>abcde</sup>  | 61.59 (10.40) <sup>de</sup>    | 64.06 (3.85) <sup>e</sup>     |
|               |        | 48       | 52.99 (2.45) <sup>abcde</sup>  | 47.05 (1.43) <sup>abcde</sup>  | 42.46 (1.66) <sup>abcde</sup>  | 59.38 (9.52) <sup>cde</sup>    | 52.35 (0.34) <sup>abcde</sup>  | 52.84 (1.89) <sup>abcde</sup> |
|               |        | 72       | 51.69 (0.32) <sup>abcde</sup>  | 47.69 (1.31) <sup>abcde</sup>  | 46.59 (2.88) <sup>abcde</sup>  | 57.10 (10.38) <sup>abcde</sup> | 50.01 (1.82) <sup>abcde</sup>  | 53.46 (1.79) <sup>abcde</sup> |

\*Standard deviation in parentheses

Different letters indicate significant differences ( $P \leq 0.05$ ) for each acid



**Table 2.** Survival (%) of strains grown in glucose, lactulose, GOS from lactulose (GOS-Lu) and from lactose (GOS-La) in the presence of  $\alpha$ -amylase and pancreatin after 1 and 3 hours of fermentation.

| Strain     | % Survival                   |                             |                              |                              |
|------------|------------------------------|-----------------------------|------------------------------|------------------------------|
|            | Carbon source                | $\alpha$ -amylase 1h        | $\alpha$ -amylase 3h         | Pancreatin 1h                |
| <b>LB</b>  |                              |                             |                              |                              |
| Glucose    | 95.74 (2.02) <sup>§a</sup>   | 99.53 (2.59) <sup>a</sup>   | 107.86 (2.95) <sup>b*</sup>  | 115.95 (2.95) <sup>c*</sup>  |
| Lactulose  | 109.45 (1.97) <sup>b*</sup>  | 99.31 (3.54) <sup>a</sup>   | 119.96 (0.22) <sup>cd*</sup> | 125.06 (14.91) <sup>d*</sup> |
| GOS-Lu     | 89.72 (0.84) <sup>c</sup>    | 98.23 (11.03) <sup>a</sup>  | 95.20 (2.82) <sup>a</sup>    | 114.45 (1.46) <sup>c*</sup>  |
| GOS-La     | 105.55 (1.43) <sup>b*</sup>  | 104.90 (3.74) <sup>b</sup>  | 106.73 (3.82) <sup>b*</sup>  | 108.00 (3.41) <sup>b*</sup>  |
| <b>LC</b>  |                              |                             |                              |                              |
| Glucose    | 100.78 (6.59) <sup>ab</sup>  | 101.66 (6.48) <sup>a</sup>  | 108.66 (5.95) <sup>b*</sup>  | 104.60 (1.59) <sup>abc</sup> |
| Lactulose  | 96.58 (0.23) <sup>a</sup>    | 99.06 (2.12) <sup>a</sup>   | 106.53 (4.72) <sup>b*</sup>  | 105.58 (3.26) <sup>bc*</sup> |
| GOS-Lu     | 108.20 (4.61) <sup>b*</sup>  | 110.45 (2.46) <sup>*b</sup> | 120.02 (6.26) <sup>d*</sup>  | 107.27 (6.98) <sup>b*</sup>  |
| GOS-La     | 105.22 (12.03) <sup>b*</sup> | 106.81 (10.80) <sup>a</sup> | 103.56 (0.21) <sup>abc</sup> | 100.54 (0.85) <sup>ab</sup>  |
| <b>LD</b>  |                              |                             |                              |                              |
| Glucose    | 105.66 (1.55) <sup>c*</sup>  | 107.70 (3.15) <sup>c</sup>  | 106.60 (2.23) <sup>b*</sup>  | 111.23 (0.28) <sup>cd*</sup> |
| Lactulose  | 103.99 (1.08) <sup>b</sup>   | 106.48 (2.56) <sup>b</sup>  | 106.71 (3.48) <sup>bc*</sup> | 107.65 (0.68) <sup>bc*</sup> |
| GOS-Lu     | 93.91 (10.28) <sup>a</sup>   | 93.05 (10.62) <sup>a</sup>  | 105.81 (9.42) <sup>bc*</sup> | 113.19 (2.63) <sup>d*</sup>  |
| GOS-La     | 95.66 (5.18) <sup>a</sup>    | 93.77 (3.93) <sup>a</sup>   | 97.27 (3.54) <sup>a</sup>    | 108.46 (0.56) <sup>bc*</sup> |
| <b>LPI</b> |                              |                             |                              |                              |
| Glucose    | 99.00 (3.13) <sup>a</sup>    | 96.87 (2.47) <sup>a</sup>   | 91.33 (5.80) <sup>b*</sup>   | 91.28 (3.48) <sup>a*</sup>   |
| Lactulose  | 106.43 (0.17) <sup>bc*</sup> | 101.92 (0.22) <sup>a</sup>  | 97.99 (13.74) <sup>ab</sup>  | 99.73 (0.48) <sup>a</sup>    |
| GOS-Lu     | 105.09 (0.00) <sup>cd*</sup> | 97.80 (0.46) <sup>a</sup>   | 100.75 (6.74) <sup>a</sup>   | 101.05 (9.82) <sup>a</sup>   |
| GOS-La     | 106.98 (4.30) <sup>d*</sup>  | 100.77 (1.35) <sup>a</sup>  | 99.27 (4.05) <sup>ab</sup>   | 97.63 (6.64) <sup>a</sup>    |
| <b>LP2</b> |                              |                             |                              |                              |
| Glucose    | 98.09 (4.42) <sup>b</sup>    | 92.63 (6.64) <sup>a*</sup>  | 97.01 (2.52) <sup>a*</sup>   | 95.82 (5.24) <sup>c*</sup>   |
| Lactulose  | 102.64 (3.15) <sup>c</sup>   | 101.56 (3.08) <sup>bc</sup> | 98.60 (1.06) <sup>abcd</sup> | 98.00 (0.66) <sup>acd</sup>  |
| GOS-Lu     | 100.15 (3.20) <sup>bc</sup>  | 100.72 (0.93) <sup>bc</sup> | 99.00 (1.67) <sup>abd</sup>  | 101.02 (0.68) <sup>b</sup>   |
| GOS-La     | 101.34 (4.10) <sup>bc</sup>  | 100.06 (3.09) <sup>bc</sup> | 99.87 (2.55) <sup>ab</sup>   | 100.49 (1.53) <sup>ab</sup>  |
| <b>LS</b>  |                              |                             |                              |                              |
| Glucose    | 96.80 (0.98) <sup>b</sup>    | 99.86 (5.95) <sup>b</sup>   | 101.55 (3.13) <sup>ab</sup>  | 104.64 (0.57) <sup>ab</sup>  |
| Lactulose  | 76.71 (0.87) <sup>a*</sup>   | 87.68 (4.92) <sup>a</sup>   | 100.16 (0.28) <sup>a</sup>   | 101.85 (0.40) <sup>a</sup>   |
| GOS-Lu     | 108.21 (4.59) <sup>c*</sup>  | 101.90 (2.18) <sup>b</sup>  | 106.31 (4.40) <sup>b*</sup>  | 108.58 (5.16) <sup>b*</sup>  |
| GOS-La     | 104.23 (6.56) <sup>c</sup>   | 100.18 (2.23) <sup>b</sup>  | 101.67 (7.82) <sup>ab</sup>  | 103.05 (6.00) <sup>a</sup>   |

<sup>§</sup>Standard deviation in parentheses

Different letters indicate significant differences ( $P \leq 0.05$ ) for each strain and treatment

\*Significant differences with 0 hours for each strain and treatment

**Table 3.** Survival (%) of strains grown in glucose, lactulose, GOS from lactulose (GOS-Lu) and from lactose (GOS-La) in the presence of bile extract and low pH after 1 and 3 hours of fermentation.

| Strain            | % Survival    |                             |                             |                              |                             |
|-------------------|---------------|-----------------------------|-----------------------------|------------------------------|-----------------------------|
|                   | Carbon source | Bile extract 1h             | Bile extract 3h             | Low pH 1h                    | Low pH 3h                   |
| <b><i>LB</i></b>  |               |                             |                             |                              |                             |
| Glucose           |               | 100.50 (1.41) <sup>§a</sup> | 96.94 (1.16) <sup>a</sup>   | 28.87 (1.16) <sup>b*</sup>   | ND                          |
| Lactulose         |               | 98.36 (0.02) <sup>a</sup>   | 98.45 (2.83) <sup>a</sup>   | 72.90 (12.23) <sup>a*</sup>  | ND                          |
| GOS-Lu            |               | 78.41 (4.96) <sup>d*</sup>  | 43.19 (6.04) <sup>b*</sup>  | 74.61 (1.61) <sup>a*</sup>   | ND                          |
| GOS-La            |               | 87.95 (1.36) <sup>e*§</sup> | 62.01 (0.82) <sup>*c</sup>  | 72.34 (0.86) <sup>a*</sup>   | ND                          |
| <b><i>LC</i></b>  |               |                             |                             |                              |                             |
| Glucose           |               | 29.84 (5.77) <sup>a*</sup>  | ND                          | 29.85 (8.73) <sup>a*</sup>   | ND                          |
| Lactulose         |               | 30.97 (4.83) <sup>a*</sup>  | ND                          | 21.91 (3.44) <sup>b*</sup>   | ND                          |
| GOS-Lu            |               | 45.08 (6.69) <sup>c*</sup>  | 38.15 (4.27) <sup>b*</sup>  | ND                           | ND                          |
| GOS-La            |               | 44.60 (4.57) <sup>c*</sup>  | 33.31 (0.85) <sup>ab*</sup> | ND                           | ND                          |
| <b><i>LD</i></b>  |               |                             |                             |                              |                             |
| Glucose           |               | 55.84 (0.38) <sup>b*</sup>  | 38.78 (11.65) <sup>a*</sup> | 60.63 (0.41) <sup>d*</sup>   | 28.03 (3.00) <sup>e*</sup>  |
| Lactulose         |               | 72.93 (6.77) <sup>d*</sup>  | 63.45 (7.77) <sup>c*</sup>  | 42.05 (0.29) <sup>b*</sup>   | ND                          |
| GOS-Lu            |               | 37.63 (1.26) <sup>a*</sup>  | 35.88 (1.40) <sup>a*</sup>  | 55.21 (6.35) <sup>c*</sup>   | ND                          |
| GOS-La            |               | 52.02 (0.13) <sup>b*</sup>  | 33.22 (1.41) <sup>a*</sup>  | 37.94 (1.08) <sup>a*</sup>   | ND                          |
| <b><i>LPI</i></b> |               |                             |                             |                              |                             |
| Glucose           |               | 95.51 (3.69) <sup>de*</sup> | 90.48 (2.30) <sup>bc*</sup> | 77.58 (2.48) <sup>a*</sup>   | ND                          |
| Lactulose         |               | 99.69 (0.36) <sup>a</sup>   | 99.57 (0.36) <sup>ae</sup>  | 73.82 (3.41) <sup>a*</sup>   | ND                          |
| GOS-Lu            |               | 92.68 (6.73) <sup>cd*</sup> | 90.07 (4.30) <sup>bc*</sup> | 22.08 (0.01) <sup>c*</sup>   | ND                          |
| GOS-La            |               | 89.93 (4.46) <sup>bc*</sup> | 87.66 (1.92) <sup>b*</sup>  | 25.76 (0.12) <sup>b*</sup>   | ND                          |
| <b><i>LP2</i></b> |               |                             |                             |                              |                             |
| Glucose           |               | 84.45 (2.04) <sup>ab*</sup> | 77.81 (0.99) <sup>c*</sup>  | 69.56 (7.01) <sup>f*</sup>   | ND                          |
| Lactulose         |               | 85.29 (0.73) <sup>ab*</sup> | 81.13 (1.04) <sup>de*</sup> | 77.39 (5.92) <sup>f*</sup>   | 29.81 (2.42) <sup>cd*</sup> |
| GOS-Lu            |               | 85.96 (2.51) <sup>b*</sup>  | 79.14 (5.15) <sup>cd*</sup> | 52.87 (2.36) <sup>e*</sup>   | 19.58 (0.13) <sup>ab*</sup> |
| GOS-La            |               | 82.45 (1.18) <sup>ae*</sup> | 73.51 (4.04) <sup>f*</sup>  | 42.75 (13.00) <sup>de*</sup> | 33.92 (0.79) <sup>bc*</sup> |
| <b><i>LS</i></b>  |               |                             |                             |                              |                             |
| Glucose           |               | 80.36 (3.32) <sup>a*</sup>  | 81.58 (7.00) <sup>a*</sup>  | ND                           | ND                          |
| Lactulose         |               | 82.30 (1.37) <sup>a*</sup>  | 82.08 (2.82) <sup>a*</sup>  | ND                           | ND                          |
| GOS-Lu            |               | 87.09 (3.56) <sup>b*</sup>  | 87.54 (1.38) <sup>b*</sup>  | 42.04 (0.22) <sup>b*</sup>   | 23.68 (0.03) <sup>a*</sup>  |
| GOS-La            |               | 83.66 (0.23) <sup>a*</sup>  | 83.31 (1.69) <sup>a*</sup>  | 46.05 (5.46) <sup>b*</sup>   | ND                          |

§Standard deviation in parentheses

Different letters indicate significant differences ( $P \leq 0.05$ ) for each strain and treatment

\*Significant differences with 0 hours for each strain and treatment

ND no detected

**Table 4.** Hydrophobicity (%) of strains grown in glucose, lactulose, GOS from lactulose (GOS-Lu) and from lactose (GOS-La).

| Carbon source | % Hydrophobicity           |                            |                           |                           |                           |                            |
|---------------|----------------------------|----------------------------|---------------------------|---------------------------|---------------------------|----------------------------|
|               | <i>LB</i>                  | <i>LC</i>                  | <i>LD</i>                 | <i>LPI</i>                | <i>LP2</i>                | <i>LS</i>                  |
| Glucose       | 46.76 (8.40) <sup>h§</sup> | 0.00 (0.00) <sup>a</sup>   | 0.00 (0.00) <sup>a</sup>  | 0.00 (0.00) <sup>a</sup>  | 0.00 (0.00) <sup>a</sup>  | 13.35 (1.29) <sup>cd</sup> |
| Lactulose     | 0.00 (0.00) <sup>a</sup>   | 6.65 (1.44) <sup>abc</sup> | 0.00 (0.00) <sup>a</sup>  | 0.00 (0.00) <sup>a</sup>  | 21.55 (8.91) <sup>e</sup> | 29.76 (11.97) <sup>f</sup> |
| GOS-Lu        | 64.05 (14.11) <sup>i</sup> | 79.47 (6.47) <sup>j</sup>  | 80.09 (0.73) <sup>j</sup> | 0.00 (0.00) <sup>a</sup>  | 28.75 (5.19) <sup>f</sup> | 15.40 (5.29) <sup>d</sup>  |
| GOS-La        | 3.73 (0.17) <sup>ab</sup>  | 62.72 (1.50) <sup>i</sup>  | 0.00 (0.00) <sup>a</sup>  | 66.38 (4.45) <sup>i</sup> | 27.90 (2.38) <sup>f</sup> | 48.57 (2.76) <sup>h</sup>  |

\*Standard deviation

§ Different letters indicate significant differences ( $P \leq 0.05$ ) for each acid

VL: Vivinal-GOS purified and GOS: galactooligosaccharides from lactulose purified.

**Figure captions**

**Figure 1.** Growth of lactobacillus strains in MRS containing different carbohydrates carbon source. (◆) Glucose, (■) Lactulose, (▲) GOS from lactulose, (X) GOS from lactose. LB (*L. bulgaricus* ATCC7517), LC (*L. casei* ATCC11578), LD (*L. delbrueckii* subsp. Lactis ATCC4797), LP1 (*L. plantarum* ATCC8014), LP2 (*L. plantarum* WCFS1), LS (*L. sakei* 23K).

**Figure 1. Hernandez-Hernandez et al.**

